Loading company analysis...
AbbVie has successfully shifted growth toward Skyrizi, Rinvoq, and neuroscience, while acquisitions, high debt, and product concentration remain central risks.
Keep researching
This is a data-generated overview, not a published Rithvik Chethan research rating. Figures use the latest usable company filing and may differ from vendor-calculated trailing metrics.
The rating combines business quality, fundamentals, growth, valuation, technicals, and risk. It is a research opinion, not a price target or prediction.
AbbVie develops and sells medicines across immunology, neuroscience, oncology, eye care, and other specialty areas. Its Allergan Aesthetics portfolio includes Botox Cosmetic, Juvederm, and related products.
The business is organized around several therapeutic portfolios:
AbbVie's strategy is to use strong cash flow from established products to fund research, licensing, acquisitions, dividends, and new commercial platforms that can replace medicines losing exclusivity.
Second-quarter revenue increased 10.2% to $16.99 billion, or 9.5% operationally. GAAP EPS increased to $2.03, while adjusted EPS increased 22.9% to $3.65.
GAAP gross margin was 74.7%, and adjusted gross margin was 84.7%. GAAP operating margin reached 37.9%, while adjusted operating margin was 48.3%. The adjusted figures exclude intangible amortization, contingent-consideration changes, and other specified items.
Immunology revenue increased 15.1% to $8.79 billion. Skyrizi increased 24.4% to $5.51 billion, and Rinvoq increased 24.5% to $2.53 billion. Humira declined 35.9% to $756 million.
Neuroscience revenue increased 20.3% to $3.23 billion, led by Vraylar, Botox Therapeutic, migraine products, and Vyalev. Oncology declined 1.5% to $1.65 billion as Imbruvica weakness offset Venclexta and Elahere growth. Aesthetics was approximately flat at $1.28 billion.
Management updated full-year adjusted EPS guidance to $13.87 to $14.07, including expected dilution from the proposed Apogee Therapeutics acquisition and year-to-date acquired research expenses.
Cash generation is strong, but debt, dividends, contingent payments, acquisitions, and pipeline investment leave less room for error than the headline free cash flow suggests.
Near $246 per share, AbbVie's equity value was approximately $436 billion. The headline trailing P/E was near 70 times because GAAP earnings include large contingent-consideration and acquisition-related expenses. The stock traded near 17.6 times the midpoint of 2026 adjusted EPS guidance.
The adjusted valuation is reasonable if Skyrizi, Rinvoq, and neuroscience continue growing and acquired assets produce returns. Investors should not ignore real cash payments, debt, dilution, and research costs simply because some are excluded from adjusted EPS.
AbbVie's live panel recalculates its EMA ribbon, 200-day EMA, RSI, MACD, volume, ATR, support, resistance, and trend after each completed daily candle. Drug approvals, trial data, patent decisions, and acquisitions can cause large gaps.
The automated panel estimates fair value gaps, order blocks, breaks of structure, changes of character, and liquidity zones. Detected areas should be treated as chart references and confirmed with price action and volume.
The main checkpoints are Skyrizi and Rinvoq growth, Humira erosion, neuroscience growth, oncology performance, Apogee closing and data, debt, and dividend coverage.
Final view: AbbVie earns a bullish 82 because Skyrizi, Rinvoq, neuroscience growth, margins, free cash flow, pipeline depth, and an adjusted valuation near 18 times earnings create a strong thesis. Debt, acquisitions, product concentration, accounting adjustments, clinical risk, and tight dividend coverage prevent a higher score.
This website and its analysis are provided for educational and informational purposes only. Nothing on this site constitutes financial, investment, legal, or tax advice, or an offer to buy or sell any security. Market data is provided by Finnhub and other third-party sources and may be delayed, incomplete, or inaccurate. The author may hold positions in securities discussed, and opinions may change without notice. Past performance does not guarantee future results. Always conduct your own research and consult a qualified financial professional before making investment decisions.
Eli Lilly is delivering exceptional growth through Mounjaro and Zepbound while expanding its cardiometabolic pipeline and manufacturing capacity.
Johnson & Johnson combines a diversified medicine pipeline and global MedTech portfolio with dependable cash flow, while patent erosion and litigation remain important risks.
UnitedHealth is showing a meaningful earnings and medical-cost recovery across UnitedHealthcare and Optum, but membership contraction, regulation, and investigations remain central risks.
Automatically refreshed from Finnhub. Open each source to evaluate how the development affects the thesis.
AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.
In late July and early August 2026, AbbVie reported stronger second‑quarter results, raised full‑year revenue guidance to about US$67.6 billion, advanced RINVOQ and BOTOX regulatory milestones, and completed a multi‑billion‑dollar mix of new fixed‑ and floating‑rate bond issuances. Together, these moves highlight how AbbVie is simultaneously expanding its immunology, neuroscience and aesthetics franchises while tapping debt markets to support its pipeline and deals such as the planned Apogee...
ABBV falls after cutting its 2026 EPS outlook to reflect the Apogee deal, despite strong Q2 results, higher revenue guidance and growth from key medicines.
AbbVie's blockbuster drugs are surging while a major acquisition looms, but a trailing P/E of 71 and one model pricing the stock nearly $50 below current levels raises a real question about whether the rally has room left to run.
Recalculated automatically from daily market data. Values are cached for one hour and use the latest completed candle. Smart money zones are algorithmic estimates and should be confirmed on the chart.
